Nuwellis, Inc. IPO - What You Need to Know

Thinking about investing in Nuwellis? Before you commit your money, let’s break down the company in plain English.

Note: This is for informational purposes only and isn’t financial advice. Always do your own research before investing!

1. What does this company do?

Nuwellis helps patients who are "waterlogged." They make medical devices for people with fluid overload, often caused by heart failure or kidney disease. Their main product, the Aquadex SmartFlow system, removes excess fluid from the blood. Doctors use it when standard medications don’t work. The system offers a more precise way to remove fluid than traditional methods.

2. How do they make money and are they growing?

Nuwellis uses a "razor-and-blade" business model. They sell the Aquadex consoles and the single-use disposable kits needed for every treatment. This creates recurring sales, as every patient session requires a new kit.

However, the company faces major financial challenges. Nuwellis has a history of losing money, with an accumulated deficit of approximately $345.5 million as of March 31, 2026. They are burning through cash quickly and need this new funding to operate through the end of 2026. If they cannot sell more Aquadex systems or raise more money, they may struggle to stay in business.

3. What is this specific offering?

As of May 2026, Nuwellis is raising about $4.4 million by selling units at $1.03 per unit. Each unit includes:

• One share of common stock (or a pre-funded warrant).
• Series A and Series B warrants: These act like coupons that let you buy more shares at a set price later.

Important: These warrants are not listed on any stock exchange. Because there is no public market for them, they are hard to sell, and you may be stuck holding them.

4. What are the main risks?

• Survival Risk: The company’s auditors have expressed doubt about Nuwellis’s ability to stay in business. This capital raise is vital for their survival.
• Regulatory Hurdles: As a medical device maker, Nuwellis faces strict FDA oversight. Failing to report issues can lead to warning letters, product seizures, or legal penalties.
• Recall Risk: If the Aquadex system has a defect, the company might have to recall it. This would cost a lot of money and damage their reputation with doctors and hospitals.
• Healthcare Reform: Their revenue depends on payments from programs like Medicare. Changes to healthcare laws could reduce the financial incentive for hospitals to use the Aquadex system.
• Compliance Risks: The company must follow complex laws regarding how they interact with doctors. Any mistakes here could get them banned from federal healthcare programs, which would be devastating.
• Accounting Issues: The company has reported "material weaknesses" in its financial reporting. This means their financial statements could contain errors or lack proper oversight.

5. Where will it trade?

Nuwellis common stock trades on the NASDAQ under the ticker symbol NUWE.

Final Tip: This is not a typical "buy and hold" investment. Because the company is fighting to survive and relies on one product line, the stock price will likely be very volatile. If you invest, treat this as a high-risk gamble rather than a stable investment. Before making a decision, search for the company’s latest "Prospectus" on the SEC’s EDGAR database and read the "Risk Factors" section—it is the most important part for understanding their shaky financial position.